Latest news with #UltraMIST
Business Insider
10-08-2025
- Business
- Business Insider
Sanuwave Health reports Q2 EPS 1c vs $1.77 last year
Reports Q2 revenue $10.2M vs $7.2M last year. 'We're pleased to have put up strong results for Q2 and to have achieved 51% revenue growth in the first six months of 2025 vs the same period in 2024 ,' said Morgan Frank, CEO. 'We sold 214 UltraMIST systems in the first six months of this year, more than we did in the full year of 2023 and an increase of 86% versus same period in 2024. Q1 and Q2 have been spent building and reshaping our sales and commercial operations teams, and as of mid July, the Company achieved full national sales coverage for the first time in my tenure as CEO. If Q1 and Q2 were the quarters of 'max disruption' Q3 is expected to be the quarter of 'max construction' as the Company builds up momentum around our new sales and marketing practices (including the launch of our first concerted marketing program) with an aim to set us up for breakout performance in Q4 2025 and 2026. The energy at our sales and commercial operations national meeting a couple of weeks ago was palpable. I think we're all looking forward to seeing what Sanuwave can become as it starts firing on all cylinders.' Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yahoo
09-08-2025
- Business
- Yahoo
SANUWAVE Health Inc (SNWV) Q2 2025 Earnings Call Highlights: Record Revenue Growth Amid Rising ...
Revenue: $10.2 million for Q2 2025, a 42% increase year-over-year. UltraMIST Systems Sold: 116 systems in Q2, a 61% increase year-over-year. Applicator Revenue: $6.4 million, representing 63% of overall revenues. Gross Margin: 78.3%, up 510 basis points from the previous year. Operating Income: $1.9 million, slightly down by $0.1 million year-over-year. Operating Expenses: $6.1 million, an increase of $2.9 million year-over-year. Net Income: $1.1 million, a decrease of $5.5 million year-over-year. EBITDA: $3.2 million for Q2 2025. Adjusted EBITDA: $3.4 million, an improvement of $1.9 million year-over-year. Cash: $8.5 million as of June 30, 2025. Guidance for Q3 Revenue: $12 million to $12.7 million. Warning! GuruFocus has detected 13 Warning Signs with SNWV. Release Date: August 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points SANUWAVE Health Inc (NASDAQ:SNWV) reported a 42% year-over-year increase in revenue for Q2 2025, reaching a new quarterly record. The company sold 116 UltraMIST systems in Q2, marking a 61% increase compared to the previous year. Gross margins remained strong at 78.3%, up 510 basis points from the previous year. The company has expanded its sales force to cover all 12 national sales territories, enhancing its commercial reach. SANUWAVE Health Inc (NASDAQ:SNWV) is preparing for its first-ever concerted outbound marketing campaign, expected to launch in October, to further drive product adoption. Negative Points Operating expenses increased significantly to $6.1 million in Q2 2025 from $3.2 million in the same period last year, driven by non-cash stock-based compensation and other factors. Net income decreased to $1.1 million in Q2 2025 from $6.6 million in Q2 2024, primarily due to lower non-cash and infrequent items. The company faces challenges in forecasting large customer sales, which impacts revenue guidance accuracy. The transition to a new applicator design will take time to impact gross margins due to existing inventory levels. The company is still in the early stages of engaging with large accounts, making it difficult to predict the timing and scale of potential sales. Q & A Highlights Q: Can you give us a sense of how the enhanced production process for applicators might impact gross margin? A: Morgan Frank, CEO: The new applicator design is expected to increase production capacity and reduce costs, potentially improving margins by 350 to 400 basis points. However, this will take time as we need to deplete existing inventory before seeing the full impact, likely by early 2026. Q: With 13 sales reps, do you envision needing to expand further? A: Morgan Frank, CEO: We are currently focused on training and optimizing our existing team. While we may add a few more reps, we believe we have sufficient coverage for national reach. Future expansion could involve sector-specific roles or regional managers. Q: What is the focus of your upcoming marketing program? A: Morgan Frank, CEO: The marketing program will target specific wound types and customer segments, such as mobile wound care, nursing homes, and hospitals. The goal is to increase awareness and adoption by demonstrating the effectiveness of UltraMIST in various settings. Q: Any updates on the senior secured debt coming due? A: Morgan Frank, CEO: We are in the process of closing a refinancing deal with favorable terms. While details are limited, the new arrangement is expected to be a significant improvement over the current debt structure. Q: Can you discuss the value and strategy around your patent portfolio? A: Morgan Frank, CEO: SANUWAVE holds a large patent portfolio related to shockwave and ultrasound technologies. We are exploring ways to extend and monetize these patents, including potential licensing deals and partnerships, though specific details are not yet available. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
31-05-2025
- Business
- Yahoo
SANUWAVE Health, Inc. (SNWV): A Bull Case Theory
We came across a bullish thesis son SANUWAVE Health, Inc. (SNWV) on @rationalformula on X(Twitter). In this article, we will summarize the bulls' thesis on SNWV. SANUWAVE Health, Inc. (SNWV)'s share was trading at $27.97 as of 28th May. SNWV's trailing P/E was 2.44 according to Yahoo Finance. An assembly line of medical devices being packed for distribution. SANUWAVE ($SNWV) presents a compelling microcap investment opportunity with a rapidly maturing turnaround, a razor/blade business model, and strong operational momentum. The company's flagship product, UltraMIST, is an FDA-cleared, non-contact ultrasound device for chronic wound treatment, reimbursed by CMS at $420 per use. With a growing installed base at over 900 sites, including the Mayo Clinic ICU, and over 60% of revenue now coming from high-margin consumables, SANUWAVE generates predictable, recurring income while physicians earn attractive margins on procedures. After facing existential challenges—over 1B shares outstanding, debt default, and no cash flow—hedge fund manager Morgan Frank took the reins as CEO in May 2023, initiating a full-scale turnaround. A 1-for-375 reverse split, strategic PIPE financing, a restructured sales org, and Nasdaq uplisting have laid the groundwork for sustainable growth. Financials have rapidly improved, with FY 2024 revenue growing 60% to $32.6M and adjusted EBITDA reaching $7.2M. The company guided to 57–61% YoY growth in Q1 2025 and expects 50% of incremental revenue to fall to the bottom line. At $30/share, the market cap is ~$255M with ~$25M in net debt, implying a ~$280M EV. Management projects ~$48–50M in 2025 revenue and ~$0.82 EPS, putting SNWV at ~36x 2025 earnings and just ~21x 2026 EPS. The company has a strong patent moat, sticky recurring revenue, and limited competition, with real near-term catalysts including litigation proceeds and insurer outreach. While CMS dependence and leverage are risks, execution thus far supports the investment case. SNWV is a profitable, fast-growing microcap with multi-year upside. For a deeper look into another standout stock in the medical devices sector, we recommend checking out our article on Medtronic plc (MDT) wherein we summarized a bullish thesis by Magnus Ofstad on Substack. SANUWAVE Health, Inc. (SNWV) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 5 hedge fund portfolios held SNWV at the end of the first quarter which was 0 in the previous quarter. While we acknowledge the risk and potential of SNWV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than SNWV but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
30-05-2025
- Business
- Yahoo
SANUWAVE Health, Inc. (SNWV): A Bull Case Theory
We came across a bullish thesis son SANUWAVE Health, Inc. (SNWV) on @rationalformula on X(Twitter). In this article, we will summarize the bulls' thesis on SNWV. SANUWAVE Health, Inc. (SNWV)'s share was trading at $27.97 as of 28th May. SNWV's trailing P/E was 2.44 according to Yahoo Finance. An assembly line of medical devices being packed for distribution. SANUWAVE ($SNWV) presents a compelling microcap investment opportunity with a rapidly maturing turnaround, a razor/blade business model, and strong operational momentum. The company's flagship product, UltraMIST, is an FDA-cleared, non-contact ultrasound device for chronic wound treatment, reimbursed by CMS at $420 per use. With a growing installed base at over 900 sites, including the Mayo Clinic ICU, and over 60% of revenue now coming from high-margin consumables, SANUWAVE generates predictable, recurring income while physicians earn attractive margins on procedures. After facing existential challenges—over 1B shares outstanding, debt default, and no cash flow—hedge fund manager Morgan Frank took the reins as CEO in May 2023, initiating a full-scale turnaround. A 1-for-375 reverse split, strategic PIPE financing, a restructured sales org, and Nasdaq uplisting have laid the groundwork for sustainable growth. Financials have rapidly improved, with FY 2024 revenue growing 60% to $32.6M and adjusted EBITDA reaching $7.2M. The company guided to 57–61% YoY growth in Q1 2025 and expects 50% of incremental revenue to fall to the bottom line. At $30/share, the market cap is ~$255M with ~$25M in net debt, implying a ~$280M EV. Management projects ~$48–50M in 2025 revenue and ~$0.82 EPS, putting SNWV at ~36x 2025 earnings and just ~21x 2026 EPS. The company has a strong patent moat, sticky recurring revenue, and limited competition, with real near-term catalysts including litigation proceeds and insurer outreach. While CMS dependence and leverage are risks, execution thus far supports the investment case. SNWV is a profitable, fast-growing microcap with multi-year upside. For a deeper look into another standout stock in the medical devices sector, we recommend checking out our article on Medtronic plc (MDT) wherein we summarized a bullish thesis by Magnus Ofstad on Substack. SANUWAVE Health, Inc. (SNWV) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 5 hedge fund portfolios held SNWV at the end of the first quarter which was 0 in the previous quarter. While we acknowledge the risk and potential of SNWV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than SNWV but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Sign in to access your portfolio
